Benchmark reiterates Buy on IMAX stock, keeps $44 target on slate

IMAX reported Q1 global box office of $260M versus Benchmark's $269M estimate, with Benchmark leaving 2026 estimates unchanged but raising a price target to $44 and Rosenblatt reiterating Buy with a $47 target. Early Q2 trends show Project Hail Mary delivering roughly $75M+ in IMAX global box office (opening weekend $28M: $16.4M domestic, $11.2M international), supporting momentum into 2026 and potential catalysts from CinemaCon and forthcoming 70mm-filmed titles. CEO Richard Gelfond is on temporary medical leave for pneumonia but is reported to be recovering; analysts point to IMAX's strong theatrical positioning and reset earnings base as justification for maintained/raised PTs.

Analysis

IMAX functions as a high-operating-leverage play on theatrical premiumization rather than a pure box-office bet. Its proprietary formats and auditorium scarcity create pricing power and per-screen yield upside when studios supply filmed-for-premium content; this translates into asymmetric economics because incremental ticket dollars drop to IMAX with limited incremental capex on the licensing side.

Second-order beneficiaries include specialized projection and 70mm service suppliers and regional exhibition groups that have slots to convert into premium auditoria; conversely, large, heavily levered chains that cannot finance upgrades or fill non-premium seats are the structural laggards. A content pipeline concentrated in a few tentpoles magnifies sequencing risk — a couple of strong IMAX-native films can re-rate the stock quickly, while content slippage or studio window experimentation could compress multiples fast.

Key catalysts cluster around trade shows and studio release calendars over the next 3–12 months where filmed-for-premium announcements and system-signing cadence will be revealed; those are binary-ish and will move sentiment more than near-term fundamentals. Tail risks include renewed China market volatility, shortening theatrical windows by studios, and any operational hiccups in rolling out premium installs (supply-chain or labor constraints) which could flip the story within a single quarter.

From a valuation-structure view, IMAX is best traded as a convex event-driven growth name: buy optionality into confirmed content and signing beats, but hedge execution and market cyclicality. Position sizing and instrument choice should reflect the binary nature of upcoming catalysts and the non-linear exposure to a small number of tentpole outcomes.

Key Decisions for Investors

• Long IMAX (IMAX) equity — 2–4% portfolio position; entry on dips or on confirmed CinemaCon/content announcements. Timeframe 6–12 months. R/R: target asymmetric 40–80% upside if filmed-for-premium momentum accelerates; stop-loss at -25% to limit exposure to a macro-driven box office drawdown.
• Long-dated call spread on IMAX (12–18 months) — buy-to-open an ITM/ATM call and sell a higher strike to fund premium. Position size 1–2% notional. Timeframe 12–18 months to capture multiple re-rating while capping max loss; expected payoff 3x+ if catalytic content pipeline and system signings materialize.
• Pair trade — long IMAX (IMAX) / short dominant, highly levered exhibitor (AMC) equal-dollar — horizon 6–12 months. Rationale: isolate premium-format revenue capture vs commoditized, balance-sheet sensitive attendance risk. Use 30% notional stop on the pair; outcome benefits if premium yields expand while general attendance is pressured.
• Tactical event trade into CinemaCon — buy 1–3 month calls or call spreads on IMAX sized for volatility (0.5–1% portfolio). Objective: capture upside from filmed-for-premium announcements and system-signing headlines. Keep small due to binary outcomes and potential IV crush if announcements are muted.